cardiovascular events associated with rofecoxib: final analysis of the approve trial.  selective inhibition of cyclo-oxygenase-2 has been associated with an increased risk of cardiovascular events in several clinical trials. the adenomatous polyp prevention on vioxx (approve) study assessed the effect of 3-year treatment with a cyclo-oxygenase-2 inhibitor, rofecoxib (25 mg), on recurrence of neoplastic polyps of the large bowel. we report the cardiovascular outcomes of a long-term follow-up of participants in the trial.